This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
cml
Chronic Myeloid Leukemia
Clonal myeloid leukemia driven by t(9;22)/BCR-ABL (Philadelphia chromosome); imatinib (IRIS trial) transformed CML from fatal to chronic; 5-year OS >85%. TKI-refractory T315I → ponatinib or asciminib; treatment-free remission achievable in ~50% of deep molecular responders.
Entry Metadata
| Field | Value |
|---|---|
| ID | cml |
| Name | Chronic Myeloid Leukemia |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417. · PubMed 17151364
- Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044-1054. · PubMed 26816503